SMMT - CIK 0001599298
Summit Therapeutics Inc. (SMMT) reported revenue of $0.00 for fiscal year 2024, as filed in its audited annual report with the SEC.
| Fiscal year | Revenue | Change |
|---|---|---|
| FY 2024 | $0.00 | - |
| FY 2023 | $0.00 | -100.0% |
| FY 2022 | $705.00K | -61.0% |
| FY 2021 | $1.81M | +110.3% |
| FY 2020 | $860.00K | +15.7% |
| FY 2019 | $743.00K | -98.7% |
| FY 2019 | $57.09M | +254.5% |
| FY 2018 | $16.10M | - |
Summit Therapeutics Inc. (SMMT) reported revenue of $0.00 for fiscal year 2024, as filed in its audited annual report with the SEC.
Between fiscal 2018 and fiscal 2024, Summit Therapeutics Inc.'s revenue declined from $16.10M to $0.00.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.